Treatment for Moderate Aortic Stenosis
For moderate aortic stenosis, medical surveillance with guideline-directed heart failure therapy is the standard approach, with surgical aortic valve replacement (SAVR) being reasonable (Class IIa) only when the patient is already undergoing coronary artery bypass grafting (CABG) or other cardiac surgery. 1
Primary Management Strategy
Medical Management
- No specific pharmacologic therapy exists to halt progression of aortic valve calcification 2
- Control blood pressure carefully, starting at low doses and titrating gradually 3
- Avoid diuretics, vasodilators, and positive inotropes in patients awaiting surgery due to risk of destabilization 1
- Statins are NOT indicated for preventing AS progression 1
- For patients with concurrent heart failure with reduced ejection fraction (HFrEF), optimize guideline-directed medical therapy 2, 4
Surveillance Approach
- Regular clinical follow-up to monitor for symptom development
- Serial echocardiography to assess progression
- Monitor for signs of cardiac damage: elevated BNP/troponin, left ventricular hypertrophy, reduced ejection fraction, or myocardial fibrosis 2
When to Consider Intervention
Clear Indication for SAVR (Class IIa)
Concomitant SAVR is reasonable when patients with moderate AS are undergoing CABG, aortic surgery, or other valve surgery 1. This recommendation exists to avoid future reoperation as AS progresses.
However, recent data challenges this approach: among patients ≥65 years undergoing CABG, those who had isolated CABG (without SAVR) had lower operative mortality and fewer postoperative complications compared to CABG+SAVR, though they faced higher rates of heart failure readmissions (25.9% vs 2.4% required AV intervention at 8 years) 5. The advent of transcatheter aortic valve replacement (TAVR) means future valve intervention no longer requires mediastinal reentry, making the decision more nuanced.
Emerging Evidence (Not Yet Guideline-Supported)
Recent observational studies show moderate AS carries increased cardiovascular risk and mortality, particularly with left ventricular dysfunction 2, 6, 7. However, the only published randomized trial (TAVR UNLOAD) failed to demonstrate prognostic benefit of early TAVI in moderate AS patients with HFrEF or HFmrEF 4.
Currently, early intervention for isolated moderate AS remains investigational and should NOT be performed outside clinical trials.
Critical Diagnostic Considerations
Before labeling AS as "moderate," ensure accurate grading:
- Confirm hemodynamic measurements are concordant (valve area, mean gradient, peak velocity)
- Rule out discordant grading that might indicate severe AS
- Use multimodality imaging when uncertainty exists 7
- Assess for left ventricular remodeling response (hypertrophy, reduced ejection fraction, fibrosis) 2, 7
Common Pitfalls to Avoid
- Do not perform isolated valve replacement for moderate AS - no evidence supports this outside of concurrent cardiac surgery
- Do not withhold blood pressure treatment - hypertension should be treated carefully with gradual titration 3
- Do not prescribe statins specifically to slow AS progression - they are ineffective for this purpose 1
- Do not use aggressive diuresis or vasodilators in patients being considered for surgery 1
Ongoing Clinical Trials
Multiple randomized trials are evaluating early intervention in moderate AS, particularly in patients with heart failure 8, 2, 6. Until these provide definitive evidence, the conservative surveillance approach remains standard of care.